IAM Stock: Dilution, SEC Filings & News

IAM Iambic Therapeutics Inc.

Price$13.38

Company About

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ

Vol Avg.

854.25 K

Inst Own

6.800%

Float & OS

9.38 M / 47.4 M

Cash/Shr

$8.6

Market Cap & Ev

762.68 M / N/A

Short Interest

0.1%

Borrow Rate

36.4288%

Days to Cover

Research Report

Customize research

Recent Articles (8)

View All

Iambic to participate in Jefferies Global Healthcare Conference

New

Globe Newswire

Nov 9, 2026, 8:00 AM

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Business Wire

Oct 26, 2026, 8:00 AM

Iambic Announces Pricing of Initial Public Offering

Business Wire

Oct 14, 2026, 6:52 PM

I-AM Capital Acquisition Company Announces Closing of Transaction with SMAAASH Entertainment, a fast-growing global virtual reality gaming and sports entertainment company

Globe Newswire

Nov 21, 2018, 2:00 PM

I-AM Capital Acquisition Company Announces Stockholder Approval of Business Combination with Smaaash Entertainment Private Limited

Globe Newswire

Nov 13, 2018, 5:15 PM

I-AM Capital Acquisition Company Announces Postponement of its Special Meeting

Globe Newswire

Oct 3, 2018, 8:30 PM

I-AM Capital Acquisition Company Announces Postponement of its Special Meeting

Globe Newswire

Sep 5, 2018, 3:00 PM

I-AM Capital Acquisition Company Confirms Payment of Funds to Extend the Period to Complete a Business Combination

Globe Newswire

Aug 22, 2018, 5:15 PM

Recent Filings

View All

Type	Title	Date Released
SCHEDULE 13G	Qatar Investment Authority (Filed by) New	Nov 9, 2026, 10:14 AM
4	Petrocheilos George C (Reporting)	Oct 19, 2026, 8:20 PM
4	Vogelstein R Jacob (Reporting)	Oct 19, 2026, 7:53 PM
4	Secora Michael (Reporting)	Oct 19, 2026, 7:51 PM
4	RASTETTER WILLIAM H (Reporting)	Oct 19, 2026, 7:49 PM
4	Rachlin Evan Lockwood (Reporting)	Oct 19, 2026, 7:47 PM
8-K	Iambic Therapeutics Completes Initial Public Offering and Adopts Amended Governance Documents	Oct 16, 2026, 5:03 PM
4	EMSTER KURT VON (Reporting)	Oct 16, 2026, 4:27 PM
4	Vogelstein R Jacob (Reporting)	Oct 16, 2026, 4:26 PM
4	TAGLIAFERRI MARY (Reporting)	Oct 16, 2026, 4:24 PM
4	Sharp Shalini (Reporting)	Oct 16, 2026, 4:22 PM
4	RASTETTER WILLIAM H (Reporting)	Oct 16, 2026, 4:21 PM

Earnings

No earnings availableNo calendar earnings available for IAM

Related Healthcare stocks

All tickers

Iambic Therapeutics Inc. IAM

Related Healthcare stocks

Related Healthcare stocks